NCT07413939RecruitingPhase 2
A Two-part, Seamless, Multicenter, Randomized, Open-label, Adaptive Phase II/III Study of the Blood-brain Barrier Penetrant RO7771950 Versus Tucatinib, Both in Combination With Trastuzumab and Capecitabine, in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2-Positive Breast Cancer, With or Without Central Nervous System Metastases
Interventions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 650
- Locations
- 193
- Primary Endpoint
- Progression-free Survival (PFS) as Determined by Blinded Independent Central Review (BICR)
Study Overview
Brief Summary
The purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecitabine, compared to tucatinib in combination with trastuzumab and capecitabine.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Pathologically documented locally advanced inoperable (LAI) or metastatic breast cancer (MBC) with confirmed HER2-positive status by central laboratory.
- •Measurable disease as per by RECIST v1.1 in stage
- •Non-measurable disease allowed in stage
- •Previously treated (stable or progressive) or previously untreated CNS metastases, or leptomeningeal metastases.
- •At least one prior line of anti-HER2-based therapy for LAI or metastatic disease.
- •Prior anti-HER2 antibody-drug conjugate (ADC), such as trastuzumab-deruxtecan (T-DXd) or trastuzumab emtansine (T-DM1), in any treatment setting. Participants without prior ADC therapy may only be enrolled if approved standard-of-care (SOC) anti-HER2 ADC is not locally accessible at screening, or if there is a prospectively documented clinical contraindication.
- •Prior tyrosine kinase inhibitor (TKI) in the (neo)adjuvant setting provided completion is > 12 months ahead of LAI occurrence. Prior treatment with TKIs for LAI/MBC is not permitted.
- •Has protocol-defined adequate organ and bone marrow function.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 or
- •Baseline left ventricular ejection fraction (LVEF) ≥ 50%.
Exclusion Criteria
- •Concurrent anti-cancer treatment, or treatment with investigational therapy within 28 days prior to initiation of study treatment.
- •Known active/untreated hepatitis B or C or chronic liver disease.
- •Clinically significant cardiovascular disease or risk, including heart failure (New York Heart Association (NYHA) ≥ II), ischemic heart disease or recent coronary events/interventions, clinically significant arrhythmias or electrocardiogram (ECG) abnormalities, QT prolongation or risk of ventricular dysrhythmias, poorly controlled hypertension, peripheral arterial disease, dilated cardiomyopathy, or unstable angina.
- •Clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia), or family history of sudden unexplained death or long QT syndrome.
- •Concomitant use of any drug or herbal medicine known to strongly inhibit or induce CYP3A4 or CYP2C8 activity, oral coumarin-derivative anticoagulants.
Arms & Interventions
Arm C - Tucatinib
Active Comparator
Intervention: Capecitabine (Drug)
Arm B - RO7771950 Dose Type 2
Experimental
Intervention: Trastuzumab (Drug)
Arm A - RO7771950 Dose Type 1
Experimental
Intervention: RO7771950 (Drug)
Arm B - RO7771950 Dose Type 2
Experimental
Intervention: RO7771950 (Drug)
Arm C - Tucatinib
Active Comparator
Intervention: Trastuzumab (Drug)
Arm B - RO7771950 Dose Type 2
Experimental
Intervention: Capecitabine (Drug)
Arm C - Tucatinib
Active Comparator
Intervention: Tucatinib (Drug)
Arm A - RO7771950 Dose Type 1
Experimental
Intervention: Capecitabine (Drug)
Arm A - RO7771950 Dose Type 1
Experimental
Intervention: Trastuzumab (Drug)
Outcomes
Primary Outcomes
Progression-free Survival (PFS) as Determined by Blinded Independent Central Review (BICR)
Time Frame: Approximately 35 months
Time from randomization to disease progression or death, according to standard criteria (Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)).
Secondary Outcomes
- Progression-free Survival in Participants with Central Nervous System Metastases (PFS-CNS) by BICR(Approximately 35 months)
- Objective Response Rate (ORR) by BICR(Approximately 35 months)
- Duration of Response (DOR) as per BICR(Approximately 35 months)
- Clinical Benefit Rate (CBR) as per BICR(Approximately 35 months)
- Health Utility Scores of the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L)(Approximately 35 months)
- Plasma Concentration of RO7771950 and its Metabolite(s) at Specified Timepoints(Approximately 35 months)
- Change from Baseline in the Columbia-suicide Severity Rating Scale (C-SSRS)(Approximately 35 months)
- Change from Baseline in Echocardiogram (ECHO)/Multiple-gated Acquisition (MUGA)(Approximately 35 months)
- Overall Survival in Full Analysis Set (OS-FAS)(Approximately 53 months)
- Incidence of Adverse Events (AEs)(Approximately 35 months)
- ORR in Participants with CNS Metastases (ORR-CNS)(Approximately 35 months)
- DOR in Participants with CNS Metastases (DOR-CNS)(Approximately 35 months)
- CBR in Participants with CNS Metastases (CBR-CNS)(Approximately 35 months)
- Changes from Baseline in Symptoms Burden in Participants With Brain Tumors(Approximately 35 months)
- Changes from Baseline in Function and Health-related Quality of Life (HRQoL)(Approximately 35 months)
- Severity of AEs(Approximately 35 months)
- Number of Participants Reporting Presence, Frequency of Occurrence, Severity, and/or Degree of Interference With Daily Activities of Symptomatic Treatment Toxicities as Assessed Through Use of the Patient-reported Outcome (PRO)-CTCAE(Approximately 35 months)
- Proportion of Participants Reporting Each Response Option at Each Assessment Timepoint by Treatment Arm for Treatment Side-effect Bother Single-item Functional Assessment of Cancer Therapy (FACT-GP5)(Approximately 35 months)
- Change from Baseline/Worsening in Symptomatic Treatment Toxicities as Assessed Through Use of the PRO-CTCAE(Approximately 35 months)
- Change from Baseline/Worsening in Symptomatic Treatment Side-effect Bother FACT-GP5(Approximately 35 months)
Investigators
Study Sites (193)
Loading locations...
Similar Trials
Recruiting
Phase 1
Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract CancerNCT07392541Tongji Hospital29
Recruiting
Phase 2
A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid TumorsNCT07321574Shanghai AB PharmaTech Ltd.110
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or BHemophiliaNCT07285460Sanofi85
Not yet recruiting
Phase 2
A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical CancerCervical CancerNCT07348861Zheng Min25
Completed
Phase 4
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis2023-504869-23-00AbbVie Deutschland GmbH & Co. KG272